Novartis Requests Patent Extension for Transplant Drug Myfortic

Novartis is seeking an extension of the ’900 patent covering its transplant drug Myfortic based on the FDA’s lengthy review time. The agency sends the review periods, which it published recently in the Federal Register, to the PTO, which then determines how long a company’s patent protection on a drug may be extended.
Generic Line